Neoadjuvant Pembrolizumab Improves Event-Free Survival in Triple-Negative Breast Cancer - The ASCO Post
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer | NEJM
Event-Free Survival Improvement Noted in KEYNOTE-522 Study for Patients With Triple-Negative Breast Cancer
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial - The Lancet Oncology
KEYNOTE-522: Neoadjuvant and Adjuvant Pembrolizumab in TNBC
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Showed Statistically Significant Event-Free Survival (EFS) Result Versus Neoadjuvant Chemotherapy Alone in High-Risk Early-Stage TNBC | Business Wire
Neoadjuvant + adjuvant pembrolizumab improves pCR in triple-negative breast cancer with lymph node involvement - Medical Conferences
Kaplan-Meier curves of overall survival of triple-negative breast... | Download Scientific Diagram
PDF) P38: KEYNOTE-522 Study of Pembro + Chemo vs. Placebo + Chemo as Neoadjuvant Treatment Followed by Pembro vs. Placebo as Adjuvant Treatment for Early TNBC: Pathologic Complete Response in Key Subgroups
KEYNOTE-522: Neoadjuvant Pembrolizumab + CT Followed by Adjuvant Pembrolizumab in TNBC
Esmo 2019 – Keynote-522 stokes adjuvant hopes for Keytruda | Evaluate
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer | NEJM
KEYTRUDA® (pembrolizumab) KEYNOTE-522
Analysis by residual cancer burden further clarifies effect of pembrolizumab - Medical Conferences
Neoadjuvant approach as a platform for treatment personalization: focus on HER2-positive and triple-negative breast cancer - ScienceDirect
2021 Update on Systemic Therapy for Breast Cancer | Published in healthbook TIMES Oncology Hematology
KEYNOTE-522 Archives - Medical Conferences
Adding Pembrolizumab to Neoadjuvant Chemotherapy Improves Outcome
Event-Free Survival Improvement Noted in KEYNOTE-522 Study for Patients With Triple-Negative Breast Cancer
KEYNOTE-522: Sensitivity Analyses Confirm Value of Neoadjuvant Pembrolizumab in Triple-Negative Breast Cancer - The ASCO Post
Immunotherapy can be considered the new standard of care in TNBC
KEYTRUDA® (pembrolizumab) KEYNOTE-522
Esmo Virtual Plenary 2021 – second time lucky for perioperative Keytruda | Evaluate
Carboplatin for Patients With Triple-Negative Breast Cancer
